Company
Elanco Animal Health Incorporated
Headquarters: Greenfield, IN, United States
Founded: 1954
Employees: 9,000
CEO: Mr. Jeffrey N. Simmons
Market Cap
$5.96 Billion
USD as of Jan. 1, 2025
Elanco Animal Health Incorporated Categories
United States Healthcare Drug Manufacturers—Specialty & GenericUnited States Healthcare United States Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $4.45 B |
| EBITDA | $876.0 M |
| Gross Profit TTM | $2.44 B |
| Profit Margin | 4.60% |
| Operating Margin | -0.49% |
| Quarterly Revenue Growth | -3.60% |
Stocks & Indices
Elanco Animal Health Incorporated has the following listings and related stock indices.
Stock: NYSE: ELAN wb_incandescent
Stock: FSX: 5EA wb_incandescent
Product & Services
Pharmaceutical drugs (animal)
Key People
R. David Hoover (Chairman) Jeff Simmons (CEO)